Stockreport

FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

FibroBiologics, Inc.  (FBLG) 
PDF Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with [Read more]